Alison M. Schram, MD; Nicoletta Colombo, MD, PhD; Edward Arrowsmith, MD; et al.
open access
JAMA Oncol. 2023;9(1):29-39. doi:10.1001/jamaoncol.2022.5218
This phase 2b nonrandomized controlled trial evaluates whether the combination of avelumab and talazoparib is effective in patients with pathogenic BRCA1/2 or ATM alterations, regardless of tumor type.
Timothy A. Yap, MBBS, PhD; Aditya Bardia, MD; Michael Dvorkin, MD, PhD; et al.
open access
JAMA Oncol. 2023;9(1):40-50. doi:10.1001/jamaoncol.2022.5228
This nonrandomized controlled trial assesses responses associated with the combination of avelumab and talazoparib in patients with different tumor types and molecular subtypes.
Mehrdad Rakaee, PhD; Elio Adib, MD; Biagio Ricciuti, MD; et al.
free access
JAMA Oncol. 2023;9(1):51-60. doi:10.1001/jamaoncol.2022.4933
This cohort study examines the accuracy of using machine learning鈥揵ased estimates of tumor-infiltrating lymphocytes from hematoxylin-eosin images to predict response to immune checkpoint inhibitors in patients with non鈥搒mall cell lung cancer.
Anthony E. Mascia, PhD; Emily C. Daugherty, MD; Yongbin Zhang, MS; et al.
open access
JAMA Oncol. 2023;9(1):62-69. doi:10.1001/jamaoncol.2022.5843
This nonrandomized trial assesses the clinical workflow feasibility and treatment-related toxic effects of FLASH radiotherapy and pain relief at the treatment sites.
-
Invited Commentary
The First FLASH Clinical Trial鈥擳he Journey of a Thousand Miles Begins With 1 Step
Lesley A. Jarvis, MD, PhD; Rongxiao Zhang, PhD; Brian W. Pogue, PhD
JAMA Oncol
Mary L. (Nora) Disis, MD; Katherine A. Guthrie, PhD; Ying Liu, PhD; et al.
free access
JAMA Oncol. 2023;9(1):71-78. doi:10.1001/jamaoncol.2022.5143
This phase 1 nonrandomized clinical trial assesses the safety and immunogenicity of 3 doses (10, 100, and 500 渭g) of a plasmid-based vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer.
Erika Rees-Punia, PhD; Christina C. Newton, MSPH; Helen M. Parsons, PhD; et al.
free access
JAMA Oncol. 2023;9(1):79-87. doi:10.1001/jamaoncol.2022.5153
This cohort study assesses the associations of time since cancer diagnosis and stage at diagnosis with the risks of pelvic, radial, and vertebral fractures among older cancer survivors vs older adults without a history of cancer.
Shuang Hao, MSc, MPH; Andrea Discacciati, PhD; Martin Eklund, PhD; et al.
open access
JAMA Oncol. 2023;9(1):88-94. doi:10.1001/jamaoncol.2022.5252
This economic evaluation study of Swedish men compares the cost-effectiveness of magnetic resonance imaging鈥揳ided screening for prostate cancer with strategies using no screening or prostate-specific antigen alone.
Andreana N. Holowatyj, PhD, MS; Mary K. Washington, MD, PhD; Sean V. Tavtigian, PhD; et al.
free access
JAMA Oncol. 2023;9(1):95-101. doi:10.1001/jamaoncol.2022.5425
This cohort study examines the prevalence and spectrum of germline sequence variations in patients with appendix cancer and the utility of germline genetic testing for this population.
Jennifer L. McQuade, MD; Hans Hammers, MD, PhD; Helena Furberg, PhD; et al.
open access
JAMA Oncol. 2023;9(1):102-111. doi:10.1001/jamaoncol.2022.5409
This pooled analysis investigates the association between pretreatment obesity and the safety of immune checkpoint inhibitors in adult patients with advanced cancer.
Linda M. Liau, MD, PhD; Keyoumars Ashkan, MD, FRCP, FRCS; Steven Brem, MD; et al.
open access
has audio
JAMA Oncol. 2023;9(1):112-121. doi:10.1001/jamaoncol.2022.5370
This nonrandomized controlled trial investigates whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care extends survival among patients with newly diagnosed or recurrent glioblastoma.
-
Podcast:
Association of DCVax-L With Extension of Survival Among Patients With Glioblastoma